Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent vs Continuous Androgen Deprivation in Stage IV Prostate Cancer
NCT00002651Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- May 1995
- Primary completion
- Jun 2013
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bicalutamide and goserelin in prostate cancer (PCa) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoints: Overall Survival at 15 years, Physical Functioning as Measured by the SF-36 at 3 months and 4 more. Started May 1995; status: completed.
02
Drugs
bicalutamidegoserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00002651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002651.